AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics AC Immune to gain access to WuXi Biologics' proprietary discovery platforms including the WuXiBody(TM) Platform used for the generation of bispecific antibodies WuXi Biologics to become a preferred partner for bioprocess development and manufacturing Lausanne, Switzerland and Shanghai, China, December 19, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases and WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the first steps of an exclusive strategic collaboration that covers biologics discovery, developmen
[Read more]
| Impact snapshot | Event time: | ACIU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACIU alerts
ACIU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic AgentGlobeNewswire
- AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Roche Alzheimer's drug fails, joining long list of trial flops [Reuters]Reuters
- Roche, AC Immune anti-Tau Alzheimer's drug fails trial [Reuters]Reuters
- More
ACIU
SEC Filings
- 10/23/20 - Form F-3
- 10/21/20 - Form 6-K
- 9/23/20 - Form 6-K
- ACIU's page on the SEC website
- More